Table 1.

PD173074 shows a high degree of selectivity for FGFR tyrosine kinase

μmol/L0.11
Kinase%±%±
AMPK940932
AURORA B806878
AURORA C797710
BRSK2938908
CAMK1872878
CDK2-Cyclin A896867
CHK185159514
CHK2828895
CK1106121155
CK2793821
c-Kit995932
c-Met932891
CSK9601000
DYRK1A97141067
DYRK210671013
DYRK384310014
EFK2101311210
EPH A2957921
ERK19169810
ERK279158014
ERK87512871
FGF-R13031
GSK3b8969415
HIPK21042984
HIPK36712804
IKKb9261005
IKKe939893
IRR1144963
JNK1808880
JNK29729015
JNK3930851
Lck651200
MAPKAPK28498312
MAPKAPK37058511
MARK3834831
MELK810848
MKK1755765
MNK17318013
MNK28713898
MSK1780845
MST2949875
MST4825562
NEK2a1041910
NEK69312866
NEK79110934
p38a MAPK9311702
P38b MAPK90108115
p38g MAPK1008985
p38s MAPK10441115
PAK411181038
PAK5874903
PAK6103151047
PDK186210612
PHK996994
PIM1761788
PIM2921854
PIM3957882
PKA9317915
PKBa887805
PKBb893968
PKCa9701050
PKCb8913786
PKCe10031003
PKCz1077975
PKD18558412
PLK18913786
PLK1859957
PRAK103131009
PRK2800826
ROCK 21087973
RSK19691083
RSK27948714
S6K192141004
SGK1100912012
SmMLCK796859
Src10369315
SRPK1861864
SYK1152956
TBK1103610615
YES18911566

NOTE: The inhibitory potential of PD173074 (0.1 and 1 μmol/L) was tested in an in vitro kinase assay using a panel of tyrosine and serine/threonine kinases as previously published (21). Results are expressed as a percentage of initial activity ± SEM.